Results
105
Companys with strong funding and high growth potential
105 companies
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
BOVN.F | SEK 4.70 | 0% | n/a | SEK 2.7b | SEK 12.58 | PS9.2x | E62.0% | n/a | Pharmaceuticals & Biotech | ||
GTHX | US$7.15 | 0.1% | 379.9% | US$378.2m | US$7.15 | PS6.5x | E57.8% | n/a | Pharmaceuticals & Biotech | ||
0RV2 | SEK 169.40 | -3.5% | -43.4% | SEK 15.0b | SEK 290.60 | PS50x | E98.4% | 0% | Pharmaceuticals & Biotech | ||
IMGN | US$31.23 | 6.6% | 617.9% | US$8.4b | US$28.95 | PS29.1x | E45.8% | n/a | Pharmaceuticals & Biotech | ||
SGEN | US$228.74 | 4.5% | 76.5% | US$43.2b | US$228.91 | PS18.8x | E71.8% | n/a | Pharmaceuticals & Biotech | ||
0A8R | US$228.95 | 4.6% | 81.1% | US$43.2b | US$229.12 | PS18.8x | E71.8% | n/a | Pharmaceuticals & Biotech | ||
IVVD | US$1.15 | 27.6% | -37.8% | US$137.4m | US$8.65 | PS60.7x | E70.4% | n/a | Pharmaceuticals & Biotech | ||
ARGX | €537.94 | -2.6% | 2.8% | €29.0b | €563.02 | PS19.5x | E58.3% | n/a | Pharmaceuticals & Biotech | ||
0A8K | US$31.24 | 6.4% | 658.3% | US$8.4b | US$29.16 | PS29.1x | E45.9% | n/a | Pharmaceuticals & Biotech | ||
BIOABS | SEK 173.90 | 5.0% | n/a | SEK 15.5b | SEK 287.79 | PS51.8x | E98.4% | 0% | Pharmaceuticals & Biotech | ||
ARGN.F | €525.60 | 0% | n/a | €29.0b | €550.11 | PS19.5x | E58.3% | n/a | Pharmaceuticals & Biotech | ||
ARDX | US$6.22 | 9.3% | 49.2% | US$1.5b | US$11.28 | PS7x | E65.9% | n/a | Pharmaceuticals & Biotech | ||
ARGXB | €486.10 | -1.2% | -0.4% | €29.2b | €508.76 | PS19.5x | E58.3% | n/a | Pharmaceuticals & Biotech | ||
0QW0 | €485.32 | -2.0% | -0.8% | €29.2b | €507.94 | PS19.6x | E58.3% | n/a | Pharmaceuticals & Biotech | ||
BRCT.F | SEK 16.90 | -1.6% | -36.9% | SEK 15.0b | SEK 27.97 | PS51.8x | E98.4% | 0% | Pharmaceuticals & Biotech | ||
AKES.F | HK$9.40 | 32.6% | n/a | HK$62.0b | HK$8.59 | PS30.1x | E54.7% | n/a | Pharmaceuticals & Biotech | ||
0HOJ | US$88.59 | 2.2% | 76.9% | US$5.6b | US$126.91 | PS15.5x | E67.4% | n/a | Pharmaceuticals & Biotech | ||
BPMC | US$86.30 | -0.3% | 65.4% | US$5.6b | US$127.35 | PS15.1x | E67.4% | n/a | Pharmaceuticals & Biotech | ||
ISEE | US$39.95 | 0.9% | 236.3% | US$5.5b | US$40.00 | PB11.6x | E59.0% | n/a | Pharmaceuticals & Biotech | ||
CSPH.F | HK$0.19 | 0% | n/a | HK$1.9b | n/a | PS3.7x | E69.5% | n/a | Pharmaceuticals & Biotech | ||
BPMU.F | CHF 51.26 | 0% | n/a | CHF 553.3m | CHF 81.26 | PS3.7x | E36.4% | 0% | Pharmaceuticals & Biotech | ||
0JDK | US$10.40 | 9.2% | 73.2% | US$3.1b | US$24.55 | PS95.8x | E66.3% | n/a | Pharmaceuticals & Biotech | ||
SLNO | US$52.79 | 8.3% | 1,013.7% | US$2.1b | US$70.29 | PB7.3x | E68.2% | n/a | Pharmaceuticals & Biotech | ||
IVBI.Y | HK$22.00 | 0% | n/a | HK$72.1b | HK$28.98 | PS8.8x | E59.4% | n/a | Pharmaceuticals & Biotech |